Company

Drug

Trial ID/ Acronym

Phase

Abstract ID

Abstract Title

Trastuzumab deruxtecan

NCT04494425/ DESTINY-Breast06

III

Oral Abstract Session - LBA1000

Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)

Abemaciclib  ± fulvestrant 

NCT05169567/ postMONARCH

III

Oral Abstract Session - LBA1001

Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial

Trastuzumab deruxtecan

NCT03529110/ DESTINY-Breast03

III

Poster Session - 3, Abstract- 1025

Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03

Inavolisib + palbociclib + fulvestrant

NCT04191499/ INAVO120

III

Oral Abstract Session - 1003

First-line inavolisib/placebo + palbociclib + fulvestrant (Inavo/Pbo+Palbo+Fulv) in patients (pts) with PIK3CA-mutated, hormone receptor-positive, HER2‑negative locally advanced/metastatic breast cancer who relapsed during/within 12 months (mo) of adjuvant endocrine therapy completion: INAVO120 Phase III randomized trial additional analyses

Sacituzumab tirumotecan

NCT05347134/ OptiTROP-Breast01

III

Clinical Science Symposium - 104

Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study

BB-1701

NCT06188559

II

Poster Session - 88, Abstract- 1110

Updated safety and antitumor activity of BB-1701 from study 101 in the multiple dose level cohort of patients with locally advanced/metastatic HER2-low expressing breast cancer

Sacituzumab govitecan ± pembrolizumab

NCT04448886

II

Oral Abstract Session - LBA1004

SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer

Erdafitinib

NCT04083976/ RAGNAR

II

Poster Session - 66, Abstract- 1088

Efficacy and safety of erdafitinib in adults with breast cancer and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial

PF-07220060

NCT04557449

I/II

Poster Session - 253, Abstract- 3108

First-in-human phase 1/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 + endocrine therapy (ET): Updated safety data in patients with HR+/HER2− mBC

BLU-222

NCT05252416/ VELA

I/II

Poster Session - 34, Abstract- 1056

BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2− breast cancer (BC)